Thermo Fisher Scientific Inc. $TMO Shares Acquired by Community Bank N.A.

Community Bank N.A. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 20.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,312 shares of the medical research company’s stock after purchasing an additional 890 shares during the quarter. Community Bank N.A.’s holdings in Thermo Fisher Scientific were worth $2,154,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Verdence Capital Advisors LLC increased its stake in Thermo Fisher Scientific by 5.9% during the 2nd quarter. Verdence Capital Advisors LLC now owns 4,481 shares of the medical research company’s stock valued at $1,817,000 after purchasing an additional 248 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Thermo Fisher Scientific by 5.6% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 34,334 shares of the medical research company’s stock valued at $13,921,000 after acquiring an additional 1,816 shares during the last quarter. Concord Wealth Partners boosted its holdings in shares of Thermo Fisher Scientific by 39.5% in the 2nd quarter. Concord Wealth Partners now owns 113 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 32 shares during the last quarter. Vest Financial LLC boosted its holdings in shares of Thermo Fisher Scientific by 39.3% in the 2nd quarter. Vest Financial LLC now owns 4,440 shares of the medical research company’s stock valued at $1,800,000 after acquiring an additional 1,252 shares during the last quarter. Finally, MGO One Seven LLC boosted its holdings in shares of Thermo Fisher Scientific by 26.7% in the 2nd quarter. MGO One Seven LLC now owns 3,204 shares of the medical research company’s stock valued at $1,299,000 after acquiring an additional 676 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on TMO. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. UBS Group increased their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Finally, Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $589.10.

Check Out Our Latest Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $524.80 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a fifty day moving average of $489.83 and a two-hundred day moving average of $447.66. The stock has a market capitalization of $198.17 billion, a PE ratio of 30.35, a P/E/G ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.